Freeline Therapeutics rises after starting bleeding disorder therapy trial
09/03/2022 14:35
** Shares of drug developer FRLN.O rise 5.4% to $1.07
** Says first patient was dosed in early-to-mid-stage
dose-confirmation trial of its drug candidate, FLT180a, for
treatment of hemophilia B, a genetic bleeding disorder
urn:newsml:reuters.com:*:nGNX2g5nC3
** Co expects to report initial data from trial in H1 2022
and to start late-stage study of treatment in 2023
** Co's drug delivers a gene involved in clotting, restoring
normal blood clot formation
** Stock down 48.7% YTD, up to last close
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))